PRF contains significantly higher cumulative growth factor concentration than PRP because it releases these therapeutic compounds gradually over 7-14 days, rather than all at once. While PRP dumps approximately 95% of its growth factors within the first 15-60 minutes after activation with calcium chloride, PRF preserves its growth factors within a three-dimensional fibrin matrix that acts as a biological time-release system. For someone treating atrophic acne scars—those indented, pitted scars that require sustained stimulation of new collagen production—this difference is clinically meaningful: PRP’s burst release creates a brief window of activity before the growth factors are depleted, whereas PRF maintains therapeutic growth factor levels throughout the critical remodeling phase of skin healing. This article explores why this concentration difference exists, how it translates to better scar outcomes, and what the latest clinical evidence shows about choosing between these two approaches.
Table of Contents
- How Does Growth Factor Timing Create a Concentration Advantage?
- The Fibrin Matrix as a Controlled-Release System
- Clinical Evidence for Scar Treatment Outcomes
- Preparation Differences and Their Impact on Concentration
- Why Rapid Growth Factor Depletion Matters—The PRP Problem
- Advanced Formulations and Modifications
- Current Evidence Base and Forward Outlook
- Conclusion
How Does Growth Factor Timing Create a Concentration Advantage?
The fundamental difference lies in how each treatment releases growth factors. PRP, when activated by calcium chloride in a clinical setting, triggers platelet degranulation almost immediately—meaning the platelets release all of their stored growth factors within minutes. This initial surge floods the tissue with bFGF (basic fibroblast growth factor), PDGF (platelet-derived growth factor), and other healing molecules, but the effect is temporary and intense. By contrast, PRF doesn’t require activation with additives; it forms a natural fibrin clot that traps platelets and leukocytes within its matrix structure, allowing them to release growth factors slowly as the fibrin scaffold itself breaks down over time. Research comparing these mechanisms shows that basic fibroblast growth factor (bFGF) levels are significantly higher in PRF than in activated PRP when measured over an extended period.
This isn’t because PRF contains more platelets than PRP—both are concentrated platelet preparations—but because PRF’s architecture preserves and extends the release timeline. A 2024 comparative study from Springer Nature found that PRF preparations maintained growth factor availability at therapeutic levels for 7-14 days, whereas PRP concentrations dropped to minimal levels within hours. For scar treatment specifically, this sustained delivery matters because collagen remodeling in scarred tissue is a slower biological process than initial clotting or wound closure. Advanced formulations like A-PRF (advanced platelet-rich fibrin) and CGF (concentrated growth factors) take this advantage further by incorporating higher leukocyte counts through improved centrifuge separation techniques. Leukocytes (white blood cells) contribute additional healing-promoting cytokines and growth factors beyond those in platelets alone, enhancing the overall therapeutic effect. Studies show A-PRF and CGF preparations contain comparable or higher levels of platelet-derived growth factors than standard PRP, with the added benefit of that sustained-release delivery model.
The Fibrin Matrix as a Controlled-Release System
Understanding the fibrin matrix is key to understanding why PRF outperforms PRP for scars. After blood is centrifuged without additives (the PRF protocol), a natural fibrin clot forms during the separation process. This isn’t just a passive byproduct—it’s an active biological scaffold. The fibrin fibers physically trap platelets and leukocytes within a three-dimensional mesh, and as the matrix gradually degrades over one to two weeks, those cells slowly release their growth factors into the surrounding tissue. This controlled-release mechanism has a specific clinical advantage for scar treatment. Atrophic (indented) acne scars require sustained, ongoing fibroblast stimulation to rebuild lost collagen over weeks.
A single bolus of growth factors—like PRP delivers—may initiate the healing cascade, but it doesn’t maintain the signaling necessary for deep, lasting remodeling of scarred tissue. PRF, maintaining growth factor availability throughout the remodeling window, keeps fibroblasts activated longer and more consistently, leading to more substantial collagen deposition. However, this advantage only applies if the scar is being mechanically treated simultaneously (such as with microneedling), because growth factors alone cannot remodel truly deep indented scars without additional trauma to stimulate new collagen formation. The fibrin scaffold also provides a structural benefit beyond just timing. It creates a moist biological environment that supports cell migration and differentiation, and it releases not just growth factors but also pro-healing cytokines that modulate inflammation—another key part of the remodeling process. PRP, by contrast, is delivered as a liquid without this structural matrix, so the growth factors disperse quickly and aren’t concentrated at the treatment site for extended periods.
Clinical Evidence for Scar Treatment Outcomes
When researchers have directly compared PRF to PRP for atrophic acne scars, the results consistently favor PRF. A 2024 systematic review published in PMC found that therapeutic response for atrophic acne scars was significantly higher in PRF-treated groups compared to PRP alone or even PRP combined with microneedling. In that study population, PRF achieved more pronounced scar improvement with less frequent retreatment needed. For rolling scars specifically—those wavy, undulating depressions common in acne-scarred skin—the data on PRF combined with microneedling is particularly compelling.
The combination of PRF’s sustained growth factor delivery plus the mechanical stimulus from microneedling needles creates a synergistic effect. Patients treated with PRF plus microneedling showed marked improvement in rolling scar depth and appearance compared to PRP plus microneedling. The timing mechanism matters here: the microneedling creates micro-injuries that trigger the initial inflammatory phase of healing, and PRF maintains growth factor support throughout the tissue remodeling that follows. One important limitation, though, is that no single treatment—PRF, PRP, or otherwise—completely eliminates severe, deep atrophic scars in one session. Multiple treatments spaced 4-6 weeks apart are typically required, and realistic patient expectations about the degree of improvement are essential.
Preparation Differences and Their Impact on Concentration
Not all PRF is created equal, and the same is true for PRP. The centrifugation speed, duration, and parameters used during preparation directly affect the final concentration of growth factors and cells. Standard PRP typically uses higher centrifuge speeds to concentrate platelets as tightly as possible, which increases platelet count but also removes some red blood cells and leukocytes from the final product. PRF, by contrast, uses lower centrifuge speeds and shorter spin times, which preserves a higher proportion of leukocytes in the final preparation. This difference in cell composition is why modern PRF preparations contain significantly higher leukocyte counts than traditional PRP.
Leukocytes contribute interleukin-1 (IL-1), tumor necrosis factor (TNF), and other immune-modulating growth factors that enhance tissue healing beyond what platelets alone provide. Studies measuring the actual concentration of these factors show that total growth factor concentration (platelets plus leukocytes combined) is higher in PRF than in standard PRP, even when platelet count alone might be similar. Advanced-PRF uses even more refined centrifugation to maximize this effect. For practitioners and patients, this means you can’t compare PRF and PRP simply by looking at platelet count. A higher-platelet-count product isn’t automatically superior if it has fewer leukocytes and releases its factors in a burst instead of gradually. The 2024 literature emphasizes that PRF’s advantage comes from both the leukocyte composition and the kinetics of release, not from raw platelet numbers alone.
Why Rapid Growth Factor Depletion Matters—The PRP Problem
The rapid depletion problem with PRP is a critical limitation that justifies why practitioners increasingly prefer PRF for scar treatment. When PRP is activated in a clinical setting with calcium chloride or similar activators, the platelets degranulate within minutes. Laboratory measurements show that within 15-60 minutes, approximately 95% of growth factors have been released from the platelets. This means that by the time the treated scar has mounted an initial cellular response to the growth factors, the stimulus is already fading. For superficial wounds or acute injuries requiring rapid hemostasis, this burst release is actually beneficial—the body needs immediate clotting and quick growth factor signaling to stop bleeding and initiate emergency healing. But for chronic scar remodeling, this fast kinetic is a disadvantage.
Scars exist in a state of altered collagen structure and reduced vascularity; they need sustained, not transient, growth factor signaling. Several hours after PRP treatment, growth factor concentrations have dropped to near-baseline levels, while fibroblasts are just beginning to sense the initial signal and mount a response. This mismatch between the duration of growth factor availability and the timeline of cellular response helps explain why multiple studies show better outcomes with PRF. One important caveat: PRP combined with microneedling still produces benefits in some patients, particularly those with very mild or superficial scars. The mechanical trauma from needling can sometimes compensate for PRP’s short availability window by creating persistent inflammatory signals. However, for deeper atrophic scars, PRP’s rapid depletion becomes a limiting factor that PRF’s extended release overcomes.
Advanced Formulations and Modifications
Beyond standard PRF, newer formulations like A-PRF and CGF (concentrated growth factors) represent refinements designed to further optimize growth factor concentration and release. A-PRF uses a specific centrifugation protocol that increases the proportion of active leukocytes and stem cell precursors trapped in the fibrin matrix. CGF uses a similar concept but with different spin parameters.
Both formulations contain comparable or higher levels of platelet-derived growth factors than PRP while maintaining the extended-release advantage of the fibrin scaffold. A practical example: a patient with severe rolling acne scars might receive A-PRF plus microneedling, which delivers higher total growth factor concentration, sustained over 7-14 days, plus the mechanical stimulus to trigger new collagen. Early 2024 data suggests outcomes with A-PRF are incrementally better than standard PRF for deep scar remodeling, though both outperform PRP.
Current Evidence Base and Forward Outlook
The 2024 and 2025 literature continues to reinforce PRF’s advantages over PRP for scar treatment. Multiple systematic reviews published in PMC and Springer Nature acknowledge that while both platelet-rich products have therapeutic value, PRF’s higher cumulative growth factor release, superior clinical outcomes for atrophic scars, and sustained mechanism of action make it the better choice for deeper, chronic scar pathology. The evidence isn’t just anecdotal—it’s based on comparative growth factor measurements and prospective clinical trials showing significantly higher therapeutic response rates.
Looking forward, the field is moving toward even more refined formulations and combination protocols. PRF combined with fractional microneedling or other collagen-stimulating techniques continues to show promise for scar treatment that was previously considered nearly untreatable. The fundamental advantage of sustained growth factor availability appears robust and unlikely to be superseded by PRP alone, though combination approaches and emerging biotechnologies may further improve outcomes.
Conclusion
PRF achieves higher growth factor concentration than PRP for scar treatment through two mechanisms: it contains higher leukocyte counts due to improved centrifuge separation, and it releases growth factors gradually over 7-14 days rather than releasing 95% within the first 15-60 minutes. This sustained delivery through a fibrin matrix scaffold means fibroblasts receive prolonged signaling to build new collagen, making PRF significantly more effective than PRP for treating atrophic acne scars, particularly rolling scars. The 2024 clinical evidence, including systematic reviews and comparative studies, consistently shows better therapeutic outcomes with PRF.
If you’re considering treatment for atrophic acne scars, ask your dermatologist or aesthetician whether they offer PRF and whether it’s combined with microneedling for your specific scar type. Multiple treatments 4-6 weeks apart are typically needed, and results are gradual rather than dramatic—but the physiological advantage of PRF’s sustained growth factor delivery translates to meaningfully better outcomes than PRP alone or even PRP with mechanical treatments. Understanding this difference helps set realistic expectations and choose the most effective treatment option available.
